Talaris Therapeutics Stock Price, News & Analysis

Talaris Therapeutics, Inc. (Nasdaq: TALS) is a late-clinical stage biotechnology company based in Boston, MA, and Louisville, KY. Specializing in the development of transformative cell therapies, Talaris aims to alleviate the burden of chronic immunosuppression in organ transplant recipients and to induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Founded on pioneering technology discovered by Dr. Suzanne Ildstad, Talaris operates its own cell processing facility in Louisville.

Recent Developments: Talaris recently announced the results of a special stockholder meeting held on October 17, 2023, where stockholders approved the issuance of shares to the stockholders of Tourmaline Bio, Inc. as part of a merger agreement. This merger, expected to close around October 19, 2023, will result in Tourmaline surviving as a direct wholly-owned subsidiary of Talaris. Post-merger, the combined company plans to operate under the name Tourmaline Bio, Inc., trading on Nasdaq under the new ticker symbol “TRML”.

In conjunction with the merger, Talaris will effect a 1-for-10 reverse stock split, reducing outstanding shares from approximately 42.8 million to about 4.28 million. Stockholders will receive cash payments for fractional shares. The reverse stock split will uniformly impact all holders and does not alter percentage ownership interests except for fractional shares.

Financial Condition & Partnerships: Talaris is supported by notable life sciences investors, including Blackstone Life Sciences, Longitude Capital, and Qiming Venture Partners USA. The merger with Tourmaline Bio will create a combined entity focusing on developing transformative medicines, with Tourmaline's lead program, TOUR006, targeting thyroid eye disease and atherosclerotic cardiovascular disease.